ABCAM PLC Abcam plc presenting at JPM Healthcare Conference
December 21 2020 - 1:00AM
RNS Non-Regulatory
TIDMABC
ABCAM PLC
21 December 2020
Abcam plc to present at the 39(th) Annual J.P. Morgan Healthcare
Conference
Cambridge, UK, December, 21, 2020 - Abcam plc (LSE: ABC; Nasdaq:
ABCM, "Abcam") announces that Alan Hirzel, Chief Executive Officer,
will present at the 39th Annual J.P. Morgan Healthcare Conference
on Thursday, January 14, 2021, at 1400 Eastern Standard Time (1900
GMT).
A live audio webcast of the presentation will be available on
Abcam's Investor website at
https://www.abcamplc.com/investors/reports-presentations/ .
Subsequently, a replay of the webcast will be available on this
same website for approximately 90 days.
For further information please contact:
James Staveley, VP, Investor Relations
+ 44 (0) 1223 696 000
james.staveley@abcam.com
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to
serve life science researchers globally to achieve their mission,
faster. Providing the research and clinical communities with tools
and scientific support, the Company offers highly validated
biological binders and assays to address important targets in
critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life
sciences, Abcam's ambition is to be the most influential company in
life sciences by helping advance global understanding of biology
and causes of disease, which, in turn, will drive new treatments
and improved health. Two-thirds of the world's 750,000 life science
researchers use Abcam's affinity binders, reagents, biomarkers and
assays and the Company's products are mentioned in over 20,000 of
the 56,000 peer-reviewed papers published each year in the life
sciences.
By actively listening to and collaborating with researchers, the
Company continuously advances its portfolio to address their needs.
A transparent programme of customer reviews and datasheets,
combined with an industry-leading validation initiative, gives
researchers increased confidence in their results.
Abcam 's eleven locations are located in the world's leading
life science research hubs, enabling local services and
multi-language support. Founded in 1998 and headquartered in
Cambridge, UK, the Company sells to more than 100 countries. Abcam
was admitted to AIM in 2005 (AIM: ABC).
To find out more, please visit www.abcam.com and
www.abcamplc.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAGPGRGPUPUGAR
(END) Dow Jones Newswires
December 21, 2020 02:00 ET (07:00 GMT)
Abcam (NASDAQ:ABCM)
Historical Stock Chart
From Apr 2024 to May 2024
Abcam (NASDAQ:ABCM)
Historical Stock Chart
From May 2023 to May 2024